合成生物学融合了工程学和分子生物学的原理，旨在设计、构建和改造具有新功能的生物系统。它涉及标准化基因元件的组装、合成基因回路的构建以及细胞代谢的重编程，从而创造出定制的生物体或生物组件。相关技术包括基因组编辑、DNA合成和通路优化，用于开发治疗、生物燃料、生物传感和生物制造等领域的应用。该领域通过构建正交系统、最小细胞和合成调控网络，加深了人们对生物复杂性的理解。以下汇编了近期发表的论文和专利，详细介绍了合成生物学在工具、方法和应用方面的创新：
这是我们最新精选的有关合成生物学的全球出版物和专利（英文），涉及众多科学在线期刊，分类并侧重于基因回路、代谢工程、dna 合成、基因组编辑、crispr cas9、合成基因组、生物砖、基因部件、蛋白质工程、细胞卡西、生物传感器、通路优化、基因表达控制、合成启动子、rna 装置、最小细胞、正交系统、基因切换开关、合成操作子、代谢途径、定向进化、合成调控网络、dna assembl、无细胞系统、合成转录、遗传密码扩充、合成生物体、代谢通量分析、合成基因和生物封闭策略。.
Probe design and electrochemical biomarker detection utilizing reusable polypeptide nucleic acid (pna) based sensors
Patent published on the 2026-05-21 in WO under Ref WO2026107321 by UNIV UTAH RES FOUND [US] (Kim Younghwan [us], Mohanty Swomitra Kumar [us])
Abstract: A biosensor apparatus includes an electrode comprising a surface including at least one of (i) a metal; and (ii) a layer of nanotubes. A plurality of peptide nucleic acid (PNA) probes are complexed to the surface of the electrode. The plurality of PNA probes are structured to bind to one or more biomarkers.[...]
Our summary: This study focuses on designing a biosensor using polypeptide nucleic acid (PNA) probes for electrochemical biomarker detection. The biosensor apparatus features an electrode with a metal surface or nanotube layer. PNA probes are attached to the electrode to selectively bind to specific biomarkers.
biosensor, peptide nucleic acid, electrochemical detection, probe design
Patent
Genetically modified aspergillus niger strain for production of citric acid and gluconic acid and methods
Patent published on the 2026-05-21 in WO under Ref WO2026105152 by DAFFODIL BIOCHEM LLP [IN] (Patel Kushal Jitu [in])
Abstract: A genetically modified strain of Aspergillus niger designated MTCC 25758 derived from parent strain Aspergillus niger ATCC 9142 through chemical mutagenesis using ethyl methane sulfonate at 1 mg/mL for 180 minutes demonstrates enhanced production capabilities for both citric acid and gluconic acid. The modified strain exhibits genetic modifications at 64 specific sequence positions that contribute to improved metabolic pathways, enhanced substrate utilization efficiency, and increased tolerance [...]
Our summary: A genetically modified Aspergillus niger strain MTCC 25758 shows enhanced production of citric acid and gluconic acid. Genetic modifications improve metabolic pathways and substrate utilization, resulting in higher yields. The strain maintains GRAS status while offering economic advantages in fermentation processes.
genetically modified organism, Aspergillus niger, citric acid production, gluconic acid production
Patent
Aspergillus niger mutant strain for production of citric acid and gluconic acid and methods
Patent published on the 2026-05-21 in WO under Ref WO2026105146 by DAFFODIL BIOCHEM LLP [IN] (Patel Kushal Jitu [in])
Abstract: An Aspergillus niger mutant strain designated MTCC 25759 derived from parent strain Aspergillus niger ATCC 9142 through chemical mutagenesis using ethyl methane sulfonate at 1 mg/mL for 30 to 60 minutes demonstrates enhanced production capabilities for both citric acid and gluconic acid. The mutant strain exhibits genetic modifications at 47 specific sequence positions that contribute to improved metabolic pathways, enhanced substrate utilization efficiency, and increased tolerance to acidic fer[...]
Our summary: The Aspergillus niger mutant strain MTCC 25759 shows enhanced production of citric acid and gluconic acid. Genetic modifications improve metabolic pathways and substrate utilization efficiency. The strain achieves 198.836 g/L gluconic acid and 0.415 g/L citric acid, offering economic advantages while maintaining GRAS status.
Aspergillus niger, mutant strain, citric acid, gluconic acid
Patent
System and method for real-time ai-based medical recommendations
Patent published on the 2026-05-21 in US under Ref US20260142030 by BOYD TIMOTHY [SE] (Gream Bianca [se], Boyd Timothy [se])
Abstract: [0000] A system for generation of medical recommendation based on patient-related data, including a processor of a medical recommendations server (MRS) node configured to host a machine learning (ML) module and connected to a patient entity node and to at least one medical emergency entity node over a network and a memory on which are stored machine-readable instructions that when executed by the processor, cause the processor to: acquire sensory data from a plurality of biosensors encapsulated [...]
Our summary: The system generates medical recommendations using patient-related data. It employs a machine learning module to analyze sensory and patient data. The recommendations are based on historical patient engagements and feature vectors derived from key classifying features.
real-time recommendations, machine learning, biosensors, artificial neural networks
Patent
Device for autonomous measurement in complex samples and for the autonomous extraction of a liquid sample
Patent published on the 2026-05-20 in EP under Ref EP4745572 by HEDBERG ELLINOR [SE] (Roxhed Niclas [se], Stemme GÖran [se], Ribet Federico [se], Hedberg Ellinor [se], GarcÍa Carmona Laura [es], Lucas Garrote Beatriz [es], Vegas GarcÍa Marta [es], GarcÍa Pellicer Marta [es], Quijano LÓpez Alfredo [es])
Abstract: Lateral flow strip for the autonomous realization of chemical and/or biological reactions in a complex liquid sample comprising at least one porous hydrophilic layer, with at least one zone of placement of the liquid sample, where the lateral flow is configured to transport the fluid along the porous hydrophilic layer, characterized in that it includes means of regulating the flow velocity of fluid along the lateral flow strip, configured to regulate the reaction time of the liquid sample in the[...]
Our summary: The device enables autonomous measurement and extraction of liquid samples. It features a lateral flow strip for conducting chemical and biological reactions. The system includes flow regulation and a biosensor for target molecule interaction.
autonomous measurement, lateral flow strip, biosensor, capillarity extraction
Patent
Production and medical use of psilocybin and related compounds
Patent published on the 2026-05-14 in AU under Ref AU2024350564 by PSYLINK UAB [LT] (Čiplys Evaldas, Korsakova Laura Martinkute, Žitkus Eimantas)
Abstract: The present invention provides a method for producing a target alkaloid from a precursor via a metabolic pathway in a recombinant yeast cell, wherein the metabolic pathway comprises a psiH enzyme, a psiK enzyme and a psiM enzyme, the method comprising culturing the recombinant yeast cell in a culture medium comprising the precursor under conditions suitable to allow the precursor to enter the recombinant host cell such that the recombinant yeast cell produces the target alkaloid, wherein the pre[...]
Our summary: This invention outlines a method for producing psilocybin using recombinant yeast cells. It involves a metabolic pathway with specific enzymes to convert a precursor into the target alkaloid. Additionally, it covers related compounds and their medical applications.
psilocybin, recombinant yeast, metabolic pathway, pharmaceutical compositions
Patent
Re-evaluating the site-directed nuclease classification as a regulatory trigger for genome-edited plant products
Published on 2026-03-05 by Osman Mewett, John McMurdy, Lieselot Bertho, Ana Atanassova, Naomi Stevens, Scott Huber, Maria Fedorova, Kevin Diehl, Kevin Tianmeng Zhao @NATURE
Abstract: Nature Biotechnology, Published online: 05 March 2026; doi:10.1038/s41587-026-03028-0Site-directed nuclease (SDN) classification into SDN-1, SDN-2 and SDN-3 outcomes is used for regulating genome-edited plant products in some countries. This reductive categorization system fails to cover the breadth of genome editing technologies developed over the past decade and their rapidly approaching commercial use. Here, we argue that, in the context of plant breeding, regulations should focus on the char[...]
Our summary: The current classification of site-directed nucleases (SDNs) is inadequate for regulating genome-edited plants. A shift towards an outcome-focused regulatory approach is proposed to enhance oversight and efficiency. This change aims to address challenges in crop improvement related to climate change and pest resistance.
genome editing, site-directed nucleases, regulatory framework, plant breeding
Publication
Ethical and Clinical Best Practices for Genome Editing Applications
Published on 2026-02-02 by Mara Ortiz-Bueno, Federica Zinghirino, Pilar Puig Serra, Kyriaki Paschoudi, Lluis Montoliu, Erden Atilla, Yonglun Luo, Alessia Cavazza, Carsten W. Lederer, Karim Benabdellah @MDPI
Abstract: Genome editing (GE) has transformed medicine by allowing precise changes to DNA, offering potential treatments for a range of inherited and acquired disorders. Several technologies support these advances, including zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeats (CRISPR)-based systems, of which the latter has emerged as the most accessible, versatile, and popular. While GE holds great promise, i[...]
Our summary: Genome editing technologies enable precise DNA modifications for medical treatments. Ethical and regulatory considerations are crucial for safe clinical applications. Regulatory agencies provide guidance on safety, consent, and compliance in genome editing practices.
Genome Editing, Ethical Standards, Regulatory Compliance, Clinical Applications
Publication
